Table 3.
SIRs of second primary cancer by type of first primary cancer and sex
| Sex | Males | Females | ||
|---|---|---|---|---|
| First primary cancer | Obs. | SIR (95% CI) | Obs. | SIR (95% CI) |
| Head/Neck/Larynx | 281 | 1.88 (1.67–2.11) | 53 | 1.74 (1.30–2.28) |
| Stomach | 111 | 0.94 (0.77–1.13) | 57 | 0.83 (0.63–1.07) |
| Colon/Rectum | 381 | 0.91 (0.82–1.00) | 233 | 0.89 (0.78–1.01) |
| Lung | 130 | 0.90 (0.75–1.06) | 56 | 1.58 (1.19–2.05) |
| Melanoma | 133 | 0.93 (0.78–1.10) | 107 | 0.94 (0.77–1.14) |
| Breast | 580 | 0.82 (0.75–0.89) | ||
| Cervix | 102 | 1.40 (1.14–1.70) | ||
| Endometrium | 177 | 1.08 (0.92–1.25) | ||
| Ovary | 72 | 1.09 (0.85–1.37) | ||
| Prostate | 1117 | 0.68 (0.64–0.72) | ||
| Bladder | 300 | 1.20 (1.07–1.34) | 61 | 1.13 (0.86–1.45) |
| Kidney | 162 | 1.22 (1.04–1.42) | 84 | 1.29 (1.03–1.59) |
| Thyroid gland | 40 | 1.23 (0.88–1.67) | 79 | 1.40 (1.11–1.75) |
| NHL high/low | 68 | 1.20 (0.93–1.53) | 43 | 1.23 (0.89–1.66) |
| CLL/ALL | 34 | 0.93 (0.64–1.30) | 22 | 1.11 (0.69–1.67) |
| All cancers combined | 3036 | 0.90 (0.86–0.93) | 1913 | 1.00 (0.96–1.05) |
| All cancers except Prostate | 1919 | 1.10 (1.05–1.15) | ||
Obs. Observed number of second primary cancers, SIR standardized incidence ratio, CI confidence interval, NHL non-Hodgkin Lymphoma, CLL chronic lymphatic leukaemia, ALL acute lymphatic leukaemia
SIRs shown in normal bold font indicate significantly increased risk, SIRs shown in bold italics indicate significantly decreased risk